Pegcetacoplan in real-world C3G and IC-MPGN patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase 4, multicountry study observes how pegcetacoplan performs outside the controlled trial setting in patients with C3G or primary IC-MPGN. It will collect real-world outcomes and safety data, and explore biomarkers not routinely measured in clinics. Researchers will review patient data before, during, and after pegcetacoplan treatment to understand its long-term benefit-risk profile and how it affects health care use. The findings aim to inform clinical decisions and disease management for these kidney conditions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Have received or plan to receive pegcetacoplan for the treatment of C3G or primary IC-MPGN.
* Provided signed and dated informed consent. For participants under the legal age signed and dated informed consent is provided by the participant's legally authorised representative. Assent will also be obtained from paediatric participants as required by local regulations.

Exclusion Criteria:

* Receiving an investigational treatment for C3G or primary IC-MPGN at the time of pegcetacoplan initiation.
* Initiated treatment with pegcetacoplan in an interventional study.

Where it's running

• Robert-Bosch-Krankenhaus
  Stuttgart, Germany Recruiting
• Keimyung University Dongsan Hospital
  Daegu, South Korea Recruiting
• Complejo Hospitalario Universitario A Coruña
  A Coruña, Spain Recruiting
• CHUV, Lausanne University Hospital
  Lausanne, Switzerland Recruiting
• Nepean Hospital
  Kingswood, Australia Not yet recruiting
• Princess Alexandra Hospital
  Woolloongabba, Australia Not yet recruiting

+51 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: Study Physician
• Email: medical.info@sobi.com
• Phone: +46 86972000

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• CPV-104 safety and drug processing in healthy adults and people with C3 glomerulopathy

  This trial tests whether CPV-104 is safe, how the body processes it, and whether the immune system reacts to it in healthy adults and adults with C3 glomerulopathy.

  Recruiting at 16 sites Phase 1 eleva GmbH · Vienna and 16 other locations · NCT07483827

• Pegcetacoplan to prevent recurrence of C3G/IC-MPGN after kidney transplant

  This study tests whether giving pegcetacoplan around the time of kidney transplant can delay or prevent recurrent C3 glomerulopathy or primary IC-MPGN in eligible patients.

  Recruiting Phase 3 Swedish Orphan Biovitrum · Recife, Pernambuco and 32 other locations · NCT07898774

• Pacritinib Effectiveness in Real-world Settings

  This real-world study will see how pacritinib works for adults with myelofibrosis by looking back at medical records from several centers.

  Recruiting at 5 sites Swedish Orphan Biovitrum · New Haven, Connecticut and 4 other locations · NCT07774455

• Assessing the effectiveness of pacritinib for VEXAS syndrome

  This study is testing if the drug pacritinib can help people with VEXAS syndrome manage their symptoms better while reducing their need for steroids.

  Recruiting at 2 sites Phase 2 Swedish Orphan Biovitrum · Scottsdale, Arizona and 38 other locations · NCT06782373

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.